偏頭痛治療市場－全球產業規模、佔有率、趨勢、機會和預測：按療法、給藥途徑、分銷管道、地區和競爭格局分類，2021-2031年

全球偏頭痛治療市場預計將從 2025 年的 43.1 億美元成長到 2031 年的 57.5 億美元，複合年成長率達到 4.92%。

神經系統疾病盛行率的不斷上升，顯著推動了抑制急性偏頭痛發作或降低慢性偏頭痛發作頻率和嚴重程度的治療市場需求。主要促進因素包括標靶治療的推出，以滿足未被滿足的醫療需求，特別是抑鈣素基因相關胜肽（CGRP）拮抗劑；此外，診斷能力的提升和患者支持服務的擴展也發揮了重要作用。這些因素正促使治療需求從傳統的疼痛管理轉向更具緩解疾病的策略。然而，新型生物製藥的高成本和有限的保險報銷政策阻礙了市場擴張。根據偏頭痛信託基金會（The Migraine Trust）的一項調查顯示，在2025年的一項調查中，92%的受訪者表示偏頭痛影響了他們的工作，這凸顯了偏頭痛帶來的巨大經濟負擔以及有效臨床管理的緊迫性。

市場促進因素

該市場的主要驅動力是CGRP抑制劑和吉泮類藥物的快速普及。與傳統的曲坦類藥物相比，這些藥物透過提供更精準、基於機制的治療方法，正在改變我們治療偏頭痛的方式。這些藥物旨在抑制與偏頭痛相關的抑鈣素基因相關胜肽（CGRP），已被核准用於急性治療和預防，並取得了顯著的商業性成功。艾伯維公司2025年10月揭露的財務資訊證實了這項成功。該公司報告稱，其Qulipta的全球淨銷售額成長了64.1%，達到2.88億美元，顯示市場正轉向針對特異性疾病的治療方法。此外，偏頭痛和頭痛疾病在全球日益普遍，也成為推動銷售量成長的主要因素，導致需要長期管理的患者群體龐大。據估計，截至2025年11月，全球將有11.6億偏頭痛患者（Frontiers預測），該疾病造成了巨大的經濟負擔。根據頭痛和偏頭痛政策論壇的報告，美國每年因頭痛和偏頭痛造成的生產力損失和醫療保健費用高達780億美元。預計發病率的上升和日益沉重的經濟負擔將持續推動對先進藥物療法的需求成長。

市場挑戰

全球偏頭痛治療市場成長的主要障礙是創新生物製藥的高昂價格，這導致醫療保險公司實施了嚴格的報銷政策。標靶治療，例如CGRP拮抗劑，滿足了重要的未滿足醫療需求，但其高昂的價格促使製藥公司實施了嚴格的准入控制策略，例如預先核准和階梯療法，以控制支出。這些複雜的進入障礙迫使製藥公司在一個臨床療效並不一定能保證廣泛可及的市場中艱難前行，商業性化應用，並限制了市場從神經系統疾病患病率上升中獲利的能力。這些報銷障礙直接減少了處方量，導致製藥公司的收入成長停滯。頭痛和偏頭痛政策論壇在 2024 年報告中指出，93% 的患者在核准處方治療之前面臨階梯治療要求，這表明這些行政限制會延誤必要的護理，阻礙患者堅持高級治療方案，從而限制市場擴張，儘管患者需求強勁。

市場趨勢

當前市場趨勢包括兒童適應症的監管核准和擴大。這將正式擴大先前依賴仿單標示外學名藥的年輕患者獲得先進生物製藥的機會。製藥公司正積極探索CGRP抑制劑的適應症擴展，以擺脫以成人為中心的收入模式，並滿足青少年族群中尚未滿足的重大需求。一個典型的例子是梯瓦製藥公司（Teva Pharmaceuticals）的AJOVY於2025年8月獲得FDA核准，用於治療6至17歲的患者。此核准是基於具有統計意義的3期臨床試驗數據，數據顯示該藥物可使患者每月平均偏頭痛發作次數減少2.5天。同時，處方數位療法（PDT）與穿戴式裝置的整合正在建構一個非藥物療法的補充治療領域。製造商透過在真實臨床環境中證明遠端電神經調節設備的療效和成本效益，成功地獲得了保險覆蓋。這使得利用數位技術來減輕高劑量治療方法副作用的混合治療方案成為可能，而這些技術正逐漸成為標準治療選擇。 Theranica公司的「Nerivio」就是一個典型的例子，預計到2025年12月，將有340萬人獲得健保覆蓋。

目錄

第1章概述

第2章：調查方法

第3章執行摘要

第4章：客戶心聲

第5章：全球偏頭痛治療市場展望

• 市場規模及預測
  • 按金額
• 市佔率及預測
  • 治療類別：{鎮痛藥（鎮痛藥、曲坦類藥物、麥角生物鹼等）及預防性藥物（抗高血壓藥、抗驚厥藥、抑鈣素基因相關胜肽 (CGRP) 拮抗劑、其他預防性療法）}
  • 給藥途徑（口服/鼻腔給藥與注射）
  • 分銷通路（零售藥局、醫院藥局、其他）
  • 按地區
  • 按公司（2025 年）
• 市場地圖

第6章：北美偏頭痛治療市場展望

• 市場規模及預測
• 市佔率及預測
• 北美洲：國別分析
  • 美國
  • 加拿大
  • 墨西哥

第7章：歐洲偏頭痛治療市場展望

• 市場規模及預測
• 市佔率及預測
• 歐洲：國別分析
  • 德國
  • 法國
  • 英國
  • 義大利
  • 西班牙

第8章：亞太地區偏頭痛治療市場展望

• 市場規模及預測
• 市佔率及預測
• 亞太地區：國別分析
  • 中國
  • 印度
  • 日本
  • 韓國
  • 澳洲

第9章：中東和非洲偏頭痛治療市場展望

• 市場規模及預測
• 市佔率及預測
• 中東與非洲：國別分析
  • 沙烏地阿拉伯
  • 阿拉伯聯合大公國
  • 南非

第10章：南美洲偏頭痛治療市場展望

• 市場規模及預測
• 市佔率及預測
• 南美洲：國別分析
  • 巴西
  • 哥倫比亞
  • 阿根廷

第11章 市場動態

• 促進因素
• 任務

第12章 市場趨勢與發展

• 併購
• 產品發布
• 近期趨勢

第13章：全球偏頭痛治療市場：SWOT分析

第14章：波特五力分析

• 產業競爭
• 新進入者的潛力
• 供應商的議價能力
• 顧客權力
• 替代品的威脅

第15章 競爭格局

• Amgen Inc.
• Teva Pharmaceutical Industries Limited
• GlaxoSmithKline plc
• Eli Lilly and Company
• Bausch Health Companies Inc.
• Novartis AG
• AbbVie Inc.
• Lundbeck Inc
• Dr. Reddy's Laboratories Limited
• Impel Pharmaceuticals Inc

第16章 策略建議

第17章：關於研究公司及免責聲明

The Global Migraine Therapeutics Market is projected to grow from USD 4.31 Billion in 2025 to USD 5.75 Billion by 2031, achieving a CAGR of 4.92%. This market, which involves pharmacological treatments to halt acute migraine attacks or lessen the frequency and intensity of chronic episodes, is significantly bolstered by the increasing prevalence of neurological conditions. Key drivers include the introduction of targeted therapies, especially calcitonin gene-related peptide (CGRP) antagonists, which address critical unmet medical needs, alongside improved diagnostic capabilities and growing patient advocacy. These factors are shifting demand from traditional pain management towards more disease-modifying strategies. However, market expansion faces challenges from the high costs of novel biologic agents and restrictive reimbursement policies. According to The Migraine Trust, 92% of participants in a 2025 survey reported that migraines impacted their work ability, underscoring the substantial economic burden and the urgent need for effective clinical management.

Market Driver

The market is primarily driven by the rapid adoption of CGRP inhibitors and gepants, which are transforming the therapeutic landscape by offering precise, mechanism-based treatments superior to traditional triptans. These drugs, designed to block the migraine-associated calcitonin gene-related peptide, have gained significant commercial traction, being approved for both acute and preventive treatment. Evidence of their success is seen in AbbVie's October 2025 financial disclosures, reporting a 64.1% increase in Qulipta's global net revenues to $288 million, indicating a shift towards disease-specific interventions. Furthermore, the increasing global prevalence of migraine and headache disorders acts as a major volume driver, creating a vast patient pool requiring long-term management. With an estimated 1.16 billion prevalent migraine cases globally by November 2025 (Frontiers), the condition imposes a substantial financial strain, with the Headache and Migraine Policy Forum reporting $78 billion in lost productivity and healthcare costs annually in the U.S. This growing incidence and economic burden ensure sustained demand for advanced pharmacotherapy.

Market Challenge

The primary obstacle to growth in the Global Migraine Therapeutics Market is the prohibitive cost of innovative biologic agents, which has prompted healthcare payers to implement restrictive reimbursement policies. Although targeted therapies like CGRP antagonists address significant unmet needs, their premium pricing leads to rigorous utilization management strategies such as prior authorization and step therapy, designed to control expenditure. These complex access barriers oblige pharmaceutical companies to navigate a market where clinical efficacy doesn't guarantee broad access, significantly impeding the commercial adoption of these specialized medications and hindering the market's ability to capitalize on the rising prevalence of neurological conditions. Such reimbursement hurdles directly reduce prescription volumes and consequently stall manufacturers' revenue growth. The Headache and Migraine Policy Forum reported in 2024 that 93% of patients faced step therapy requirements before their prescribed treatment was approved, demonstrating how these administrative restrictions delay essential care and discourage adherence to advanced treatment plans, thereby limiting market expansion despite strong patient demand.

Market Trends

Current market trends include the expansion of regulatory approvals and label indications for pediatric use, which formally extends access to advanced biologics for younger patients who previously relied on off-label generics. Pharmaceutical companies are actively seeking label extensions for CGRP inhibitors to address the considerable unmet needs in adolescents, moving beyond an adult-focused revenue model. A key example is Teva Pharmaceuticals' August 2025 FDA approval for AJOVY in patients aged 6 to 17, based on Phase 3 trial data showing a statistically significant reduction of 2.5 monthly migraine days. Concurrently, the integration of Prescription Digital Therapeutics (PDTs) and wearables is establishing a complementary non-pharmacological treatment vertical. Manufacturers are successfully securing commercial payer coverage for remote electrical neuromodulation devices by demonstrating real-world efficacy and cost-effectiveness. This allows for hybrid treatment protocols where digital interventions can mitigate the side effects associated with heavy medication regimens, positioning these technologies as standard-of-care options, as exemplified by Theranica's Nerivio gaining coverage for an additional 3.4 million lives by December 2025.

Key Market Players

• Amgen Inc.
• Teva Pharmaceutical Industries Limited
• GlaxoSmithKline plc
• Eli Lilly and Company
• Bausch Health Companies Inc.
• Novartis AG
• AbbVie Inc.
• Lundbeck Inc
• Dr. Reddy's Laboratories Limited
• Impel Pharmaceuticals Inc

Report Scope

In this report, the Global Migraine Therapeutics Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Migraine Therapeutics Market, By Therapeutics

• Pain-relieving Medications
• Preventive Medications

Migraine Therapeutics Market, By Route of Administration

• Oral & Nasal
• Injectables

Migraine Therapeutics Market, By Distribution Channel

• Retail Pharmacy
• Hospital Pharmacy
• Others

Migraine Therapeutics Market, By Region

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Migraine Therapeutics Market.

Available Customizations:

Global Migraine Therapeutics Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Migraine Therapeutics Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Therapeutics {Pain-relieving Medications (Analgesics, Triptans, Ergot Alkaloids, Others), and Preventive Medications (Blood pressure-lowering Medications, Anticonvulsant Drugs, Calcitonin Gene-related Peptide (CGRP) Antagonists, Other Preventative Therapies)}
  • 5.2.2. By Route of Administration (Oral & Nasal v/s Injectables)
  • 5.2.3. By Distribution Channel (Retail Pharmacy, Hospital Pharmacy, Others)
  • 5.2.4. By Region
  • 5.2.5. By Company (2025)
• 5.3. Market Map

6. North America Migraine Therapeutics Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Therapeutics
  • 6.2.2. By Route of Administration
  • 6.2.3. By Distribution Channel
  • 6.2.4. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Migraine Therapeutics Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Therapeutics
      • 6.3.1.2.2. By Route of Administration
      • 6.3.1.2.3. By Distribution Channel
  • 6.3.2. Canada Migraine Therapeutics Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Therapeutics
      • 6.3.2.2.2. By Route of Administration
      • 6.3.2.2.3. By Distribution Channel
  • 6.3.3. Mexico Migraine Therapeutics Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Therapeutics
      • 6.3.3.2.2. By Route of Administration
      • 6.3.3.2.3. By Distribution Channel

7. Europe Migraine Therapeutics Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Therapeutics
  • 7.2.2. By Route of Administration
  • 7.2.3. By Distribution Channel
  • 7.2.4. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Migraine Therapeutics Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Therapeutics
      • 7.3.1.2.2. By Route of Administration
      • 7.3.1.2.3. By Distribution Channel
  • 7.3.2. France Migraine Therapeutics Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Therapeutics
      • 7.3.2.2.2. By Route of Administration
      • 7.3.2.2.3. By Distribution Channel
  • 7.3.3. United Kingdom Migraine Therapeutics Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Therapeutics
      • 7.3.3.2.2. By Route of Administration
      • 7.3.3.2.3. By Distribution Channel
  • 7.3.4. Italy Migraine Therapeutics Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Therapeutics
      • 7.3.4.2.2. By Route of Administration
      • 7.3.4.2.3. By Distribution Channel
  • 7.3.5. Spain Migraine Therapeutics Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Therapeutics
      • 7.3.5.2.2. By Route of Administration
      • 7.3.5.2.3. By Distribution Channel

8. Asia Pacific Migraine Therapeutics Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Therapeutics
  • 8.2.2. By Route of Administration
  • 8.2.3. By Distribution Channel
  • 8.2.4. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China Migraine Therapeutics Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Therapeutics
      • 8.3.1.2.2. By Route of Administration
      • 8.3.1.2.3. By Distribution Channel
  • 8.3.2. India Migraine Therapeutics Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Therapeutics
      • 8.3.2.2.2. By Route of Administration
      • 8.3.2.2.3. By Distribution Channel
  • 8.3.3. Japan Migraine Therapeutics Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Therapeutics
      • 8.3.3.2.2. By Route of Administration
      • 8.3.3.2.3. By Distribution Channel
  • 8.3.4. South Korea Migraine Therapeutics Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Therapeutics
      • 8.3.4.2.2. By Route of Administration
      • 8.3.4.2.3. By Distribution Channel
  • 8.3.5. Australia Migraine Therapeutics Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Therapeutics
      • 8.3.5.2.2. By Route of Administration
      • 8.3.5.2.3. By Distribution Channel

9. Middle East & Africa Migraine Therapeutics Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Therapeutics
  • 9.2.2. By Route of Administration
  • 9.2.3. By Distribution Channel
  • 9.2.4. By Country
• 9.3. Middle East & Africa: Country Analysis
  • 9.3.1. Saudi Arabia Migraine Therapeutics Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Therapeutics
      • 9.3.1.2.2. By Route of Administration
      • 9.3.1.2.3. By Distribution Channel
  • 9.3.2. UAE Migraine Therapeutics Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Therapeutics
      • 9.3.2.2.2. By Route of Administration
      • 9.3.2.2.3. By Distribution Channel
  • 9.3.3. South Africa Migraine Therapeutics Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Therapeutics
      • 9.3.3.2.2. By Route of Administration
      • 9.3.3.2.3. By Distribution Channel

10. South America Migraine Therapeutics Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Therapeutics
  • 10.2.2. By Route of Administration
  • 10.2.3. By Distribution Channel
  • 10.2.4. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil Migraine Therapeutics Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Therapeutics
      • 10.3.1.2.2. By Route of Administration
      • 10.3.1.2.3. By Distribution Channel
  • 10.3.2. Colombia Migraine Therapeutics Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Therapeutics
      • 10.3.2.2.2. By Route of Administration
      • 10.3.2.2.3. By Distribution Channel
  • 10.3.3. Argentina Migraine Therapeutics Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Therapeutics
      • 10.3.3.2.2. By Route of Administration
      • 10.3.3.2.3. By Distribution Channel

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global Migraine Therapeutics Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. Amgen Inc.
  • 15.1.1. Business Overview
  • 15.1.2. Products & Services
  • 15.1.3. Recent Developments
  • 15.1.4. Key Personnel
  • 15.1.5. SWOT Analysis
• 15.2. Teva Pharmaceutical Industries Limited
• 15.3. GlaxoSmithKline plc
• 15.4. Eli Lilly and Company
• 15.5. Bausch Health Companies Inc.
• 15.6. Novartis AG
• 15.7. AbbVie Inc.
• 15.8. Lundbeck Inc
• 15.9. Dr. Reddy's Laboratories Limited
• 15.10. Impel Pharmaceuticals Inc

16. Strategic Recommendations

17. About Us & Disclaimer